The Manufacturers Life Insurance Company decreased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 63.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 147,961 shares of the biopharmaceutical company’s stock after selling 260,970 shares during the period. The Manufacturers Life Insurance Company owned 0.14% of Regeneron Pharmaceuticals worth $92,260,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. SHP Wealth Management acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at $26,000. Western Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth $26,000. Titan Wealth CI Ltd bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth $29,000. Mowery & Schoenfeld Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $29,000. Finally, Trust Co. of Vermont acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $29,000. 83.31% of the stock is currently owned by institutional investors.
Regeneron Pharmaceuticals Stock Performance
REGN stock opened at $781.49 on Friday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $541.00 and a 1-year high of $859.34. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The firm has a market cap of $80.46 billion, a PE ratio of 19.32, a P/E/G ratio of 1.56 and a beta of 0.20. The business’s 50-day moving average price is $754.93 and its two-hundred day moving average price is $720.58.
Regeneron Pharmaceuticals Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were paid a $0.94 dividend. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is presently 9.29%.
Analysts Set New Price Targets
Several research firms have weighed in on REGN. Guggenheim increased their target price on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. BMO Capital Markets cut their price target on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a research report on Monday, May 18th. Wells Fargo & Company lifted their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a research note on Friday, July 31st. Finally, Sanford C. Bernstein upgraded shares of Regeneron Pharmaceuticals to a “hold” rating in a report on Wednesday, July 29th. Fourteen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $802.18.
Get Our Latest Research Report on Regeneron Pharmaceuticals
Key Regeneron Pharmaceuticals News
Here are the key news stories impacting Regeneron Pharmaceuticals this week:
- Positive Sentiment: RBC said Regeneron is increasingly likely to retain key patent protection for Eylea HD, a major commercial product. Preserving exclusivity could help protect revenue and earnings from biosimilar competition. Regeneron Pharmaceuticals More Likely to Retain Eylea HD Patent, RBC Says
- Positive Sentiment: HSBC raised its price target on REGN to $920 from $800 and maintained a Buy rating, implying substantial upside from the referenced share price. The move signals improved confidence in Regeneron’s outlook. HSBC Raises Regeneron Price Target
- Neutral Sentiment: A reported September short-interest figure of zero shares is not actionable because it is inconsistent with normal market data and produces a zero-day short-interest ratio.
- Negative Sentiment: Multiple law firms are promoting a securities class action against Regeneron, with a September 14 deadline for investors to seek lead-plaintiff status. The repeated notices add reputational and potential legal-cost risks, although they largely repeat the same lawsuit information rather than announce a new development. Regeneron Investor Deadline and Class Action Lawsuit
- Negative Sentiment: The lawsuit stems from the failure of a Phase 3 melanoma trial involving the Fianlimab-Libtayo therapy and allegations that Regeneron minimized statistical and protocol risks, including issues affecting progression-free-survival analysis. The trial failure reportedly erased about $11 billion in market value and raises concerns about the company’s pipeline and disclosure practices. Regeneron Clinical-Trial Risk Disclosure Lawsuit
Insider Activity at Regeneron Pharmaceuticals
In other news, Director Huda Zoghbi sold 800 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. This represents a 31.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,215 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $1,032,750.00. Following the sale, the executive vice president directly owned 13,134 shares of the company’s stock, valued at $11,163,900. This represents a 8.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 4,146 shares of company stock worth $3,432,488. Corporate insiders own 6.97% of the company’s stock.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.
Regeneron’s marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.
Read More
- Five stocks we like better than Regeneron Pharmaceuticals
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
